Announced details
Therapeutic development for facioscapulohumeral muscular dystrophy (FSHD)
Suppression of expression of DUX4 and its target gene group was confirmed and evaluated. The specific suppression rate is not disclosed.
The organizer of the conference at which the Company will present its research results. Capital and personnel relationships are not disclosed.
An organization that hosts an international conference featuring research presentations on FSHD. Its location, representative, capital, and year of establishment are not disclosed.
Rosemont, Illinois, United States (conference venue)
No impact on financial results is provided
The company does not address Contract Value / Offering price.
The program for the FSHD Society 2026 International Research Congress and the FSHD Society website
| Item | Details |
|---|---|
| Names of Products / Services Covered | MDL-103, CRISPR-GNDM® technology |
| Counterparty | FSHD Society |
| Counterparty overview | An organization that hosts an international conference featuring research presentations on FSHD. Its location, representative, capital, and year of establishment are not disclosed. |
| Relationship with the Company | The organizer of the conference at which the Company will present its research results. Capital and personnel relationships are not disclosed. |
| Launch date | 25–26 June 2026 (scheduled) |
| Applicable area | Therapeutic development for facioscapulohumeral muscular dystrophy (FSHD) |
| Location | Rosemont, Illinois, United States (conference venue) |
| Quantitative Effects | Suppression of expression of DUX4 and its target gene group was confirmed and evaluated. The specific suppression rate is not disclosed. |
| Impact on Business Performance | No impact on financial results is provided |
| Source | The program for the FSHD Society 2026 International Research Congress and the FSHD Society website |
Items this document does not state (8)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To share research results on MDL-103, which aims to suppress expression of DUX4, the causative gene of FSHD.